Anavex Life Sciences Corp (AVXL)

[dholmes791]

The stock has moved this year because of near term catalysts...not "basically nothing".

-- Complete data ANAVEX®2-73 U.S. Rett syndrome Phase 2 study – expected Q2 2021
-- Complete data ANAVEX®2-73 Parkinson’s disease dementia (PDD) Phase 2 study – expected Q2 2021
-- Top-line data AVATAR: Potentially pivotal Phase 2/3 adult RTT clinical trial – expected mid 2021
-- Top-line data Phase 1 ANAVEX®3-71 clinical trial – expected mid 2021
-- Top-line data EXCELLENCE: Potentially pivotal Phase 2/3 pediatric RTT clinical trial – expected 2H
2021
-- Top-line data ANAVEX®2-73-AD-004: Potentially pivotal Phase 2b/3 AD clinical trial – expected 1H 2022
-- Initiation of ANAVEX®2-73 imaging-focused Parkinson’s disease clinical trial – expected 2021
-- Pipeline expansion opportunities for ANAVEX®2-73
-- Initiation of potentially pivotal Phase 2/3 Fragile X clinical trial – expected 2021
-- Initiation of potentially pivotal Phase 2/3 clinical trial for the treatment of a new, rare disease
indication – expected 2021

~ 230M shares have traded between 11$-28$. That's over 3x the current O/S of 70,030,620(March 29, 2021)

Seems like it has consolidated well in this $11-$16 range. Volume feels relatively anemic at the lower end of this range.